Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00618527 (ClinicalTrials.gov)	August 2006	6/2/2008	Combination Therapy Using Cellcept and Rebif in RRMS	Combination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: mycophenolate mofetil (Cellcept);Drug: human interferon beta 1a (Rebif)	Aaron Boster	EMD Serono;Pfizer	Completed	18 Years	65 Years	Both	31	Phase 0	United States
2	NCT00324506 (ClinicalTrials.gov)	May 2006	9/5/2006	Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis	A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Mycophenolate Mofetil (CellCept)	University of Texas Southwestern Medical Center	Aspreva Pharmaceuticals	Completed	18 Years	55 Years	Both	43	Phase 2	United States
3	NCT00223301 (ClinicalTrials.gov)	July 2004	19/9/2005	Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis	A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis	Multiple Sclerosis	Drug: Mycophenolate Mofetil (cellcept)	University of Texas Southwestern Medical Center	Roche Pharma AG;Biogen Idec	Completed	21 Years	45 Years	Both	24	Phase 2/Phase 3	United States